In a phase 1 trial, administration of a protein-based vaccine derived from amino acids 676-1255 of the intracellular domain of HER2 plus GM-CSF resulted in HER2-specific T cell and antibody immunity in patients with stage II-IV HER2+ breast and ovarian cancer (78). This evidence concerns the gene ERBB2 and ovarian cancer.